Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study
Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for...
ETR: BAYN
Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication
Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA)...
EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment
Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...
Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors
Germany-based pharmaceutical giant Bayer AG (ETR: BAYN) has announced the initiation of a Phase I...
Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation
Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...
Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care
Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the...
Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation
Germany-based Bayer AG (ETR: BAYN) has announced the opening of its new life science incubator,...
Bayer’s Nubeqa Files for FDA Approval in mHSPC
German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug...
Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing
China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...
Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan
Germany-based Bayer AG (ETR: BAYN) has announced a significant collaboration and license agreement with US-based...
Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...
Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals
Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6%...
Bayer AG Receives FDA 510(k) Clearance for MEDRAD Centargo CT Injection System
Germany-based Bayer AG (ETR: BAYN) has announced that it has received 510(k) clearance from the...
AskBio’s AB-1003 Receives Rare Pediatric Disease and Orphan Drug Designations from FDA
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned subsidiary of Bayer AG (ETR: BAYN), has announced...
Bayer’s Leap Forward: Implementing Salesforce on Alibaba Cloud for Customer Engagement
Bayer (ETR: BAYN) has announced that its China Prescription Medicines business has fully adopted the...
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...
Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration
Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the...
Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China
Bayer AG (ETR: BAYN), a leading German multinational pharmaceutical and life sciences company, has expanded...
Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a leading German life sciences company, announced...
Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors
Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial...